Grant: Engage Grants Program
Université du Québec à Montréal
$25,000.00
Angiopep-coated nanoparticles for the delivery of therapeutic drugs in the brain
FY 2013-14
Summary
The blood brain barrier (BBB) is an important physiological obstacle to deliver drugs to the brain. Access toneuronal tissues is particularly important for brain cancer and degenerative diseases such as Alzheimer andParkinson. Angiochem Inc., a Montréal(Qc)-based biopharmaceutical company involved in new drugdevelopment, has identified a peptide, called Angiopep, capable of transporting diverse molecules, includingdrugs that can cross the BBB. The present proposal is to evaluate the capabilities, safeties and efficiencies toconjugate Angiopep proprietary peptide to different families of novel nanoparticles. Three families of dendriticnanoparticles will be evaluated as carriers of Angiopep to evaluate their properties since they may appear asbeing more efficacious. The new molecules will represent novel entities that can also be used for brain imagingfollowing injuries. In addition, a particular enzyme and its encoding gene (IDUA) will be attached to thenanoparticles to address lysosomal storage diseases. IDUA is encoding for an enzyme that will help regulatethe accumulation of glycosaminoglycans in the brain that form important tissue damages. Prof. Roy hasdeveloped an international renowned expertise in the design of small, monodisperse nanoparticles calleddendrimers. His unique expertise will be combined to those of Angiochem Inc. to provide the company betterportfolio protection together with allowing it to widen its expertise in novel nanomedicine, a field of researchactivities gaining increasing momentum in new drug development. This new partnership is likely to conduct tocloser scientific exchange and fruitful collaboration.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
461684-2013
Name nom
Roy, René
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Angiopep-coated nanoparticles for the delivery of therapeutic drugs in the brain
Keyword
NSERC
Application summary
The blood brain barrier (BBB) is an important physiological obstacle to deliver drugs to the brain. Access toneuronal tissues is particularly important for brain cancer and degenerative diseases such as Alzheimer andParkinson. Angiochem Inc., a Montréal(Qc)-based biopharmaceutical company involved in new drugdevelopment, has identified a peptide, called Angiopep, capable of transporting diverse molecules, includingdrugs that can cross the BBB. The present proposal is to evaluate the capabilities, safeties and efficiencies toconjugate Angiopep proprietary peptide to different families of novel nanoparticles. Three families of dendriticnanoparticles will be evaluated as carriers of Angiopep to evaluate their properties since they may appear asbeing more efficacious. The new molecules will represent novel entities that can also be used for brain imagingfollowing injuries. In addition, a particular enzyme and its encoding gene (IDUA) will be attached to thenanoparticles to address lysosomal storage diseases. IDUA is encoding for an enzyme that will help regulatethe accumulation of glycosaminoglycans in the brain that form important tissue damages. Prof. Roy hasdeveloped an international renowned expertise in the design of small, monodisperse nanoparticles calleddendrimers. His unique expertise will be combined to those of Angiochem Inc. to provide the company betterportfolio protection together with allowing it to widen its expertise in novel nanomedicine, a field of researchactivities gaining increasing momentum in new drug development. This new partnership is likely to conduct tocloser scientific exchange and fruitful collaboration.